111In-Pentetreotide (OctreoScan) scintigraphy in the staging of small-cell lung cancer. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Genestreti, Giovenzio; Bongiovanni, Alberto; Burgio, Marco Angelo; Burgio, Salvatore Luca; Musto, Alessandra; Rossi, Alice; Monti, Manuela; Scarpi, Emanuela; Ulivi, Paola; Bravaccini, Sara; Dubini, Alessandra; Matteucci, Federica; Gavelli, Giampaolo
• Is Part Of: Nuclear medicine communications. Volume 36:Issue 2(2015:Feb.)
• Publication Date: 2015-02
• Subjects: Nuclear medicine -- Periodicals; 616.07575
• DOI: 10.1097/MNM.0000000000000221
• Languages: English
• ISSNs: 0143-3636

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>Background</title> <p>Small-cell lung cancer (SCLC) may express somatostatin transmembrane receptors (SSTRs) in 50–75% of cases. We evaluated the accuracy and prognostic significance of somatostatin receptor scintigraphy (SSRS) in staging compared with conventional radiological procedures.</p> </sec> <sec> <title>Patients and methods</title> <p>Newly diagnosed SCLC patients underwent scintigraphy with the radiolabeled somatostatin analog indium-111 (<sup>111</sup>In)-pentetreotide (OctreoScan). Histological data were available for 20 (38%) patients for immunohistochemical analysis of SSTR-2 expression.</p> </sec> <sec> <title>Results</title> <p>From May 2007 to December 2011 we analyzed 52 SCLC patients. In comparison with standard radiologic staging, the sensitivity and specificity of SSRS were 63 and 100% for primary pulmonary tumor (T), 51 and 100% for mediastinal lymph node (N), and 23 and 91% for metastatic disease (M), respectively. The overall SSRS accuracy was 65% for T, 62% for N, and 52% for M. Patients with positive SSRS achieved a disease control rate of 97 versus 84% in those with negative exam results; median progression-free survival was 9.5 months versus 11.0 and median overall survival was 15.3 versus 14.5 months for patients with positive SSRS versus those with a negative result. Notably, seven (78%) patients with a positive quantitative analysis for SSTR-2 had a positive SSRS; at semiquantitative analysis this correlation was found in eight (73%) patients.</p> </sec> <sec> <title>Conclusion</title> <p>SSRS has a lower accuracy in comparison with standard radiological staging in SCLC. However, patients with a positive SSRS given standard treatments showed better disease control compared with those with a negative SSRS, but similar progression-free survival and overall survival.</p> </sec> </abstract>